Sorafenib triggers apoptosis in human liver cancer cells by suppressing the signaling pathways, phosphatidylinositol-3-kinase (PI3K), protein kinase B (Akt), mammalian target of rapamycin (mTOR), and ERK [6], resulting in the activation of Bax and suppression of Bcl-2, which induces caspase-3 and Poly (ADP-ribose) polymerase expression in LM3 HCC cells [7]. Here, AKT1 is linked to liver cancer.